Logo

LFMD

LifeMD, Inc.

LFMD

LifeMD, Inc. • NASDAQ
$3.83 ▼ -0.26% (-0.01)
Market Cap $184.36 M
52w High $15.84
52w Low $3.43
Dividend Yield 0%
P/E -15.32
Volume 438.83K
Outstanding Shares 48.14M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $60.172M ▼ $54.734M ▼ $-3.806M ▼ -6.325% ▼ $-0.099 ▼ $-133.334K ▼
Q2-2025 $62.218M ▼ $55.694M ▲ $-2.075M ▼ -3.335% ▼ $-0.064 ▼ $1.916M ▼
Q1-2025 $65.698M ▲ $54.511M ▲ $1.385M ▲ 2.108% ▲ $0.01 ▲ $5.2M ▲
Q4-2024 $64.255M ▲ $53.806M ▲ $-106.272K ▲ -0.165% ▲ $-0.02 ▲ $3.565M ▲
Q3-2024 $53.272M $52.255M $-4.658M -8.744% $-0.14 $-1.439M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $23.786M ▼ $65.983M ▼ $62.615M ▼ $1.314M ▲
Q2-2025 $36.228M ▲ $73.565M ▼ $73.182M ▼ $-1.783M ▲
Q1-2025 $34.393M ▼ $73.614M ▲ $74.007M ▼ $-2.329M ▲
Q4-2024 $35.005M ▼ $72.46M ▼ $76.505M ▼ $-5.486M ▲
Q3-2024 $37.587M $72.56M $78.515M $-7.72M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-4.67M ▼ $-147.136K ▼ $-3.594M ▲ $-8.701M ▼ $-12.443M ▼ $6.42M ▼
Q2-2025 $-1.57M ▼ $8.639M ▲ $-3.7M ▼ $-3.105M ▼ $1.835M ▲ $11.507M ▲
Q1-2025 $1.917M ▲ $3.068M ▲ $-2.867M ▼ $-812.563K ▲ $-611.514K ▲ $201.049K ▲
Q4-2024 $234.691K ▲ $1.568M ▼ $-2.721M ▲ $-1.43M ▼ $-2.582M ▼ $-1.152M ▼
Q3-2024 $-5.477M $6.203M $-3.493M $-825.583K $1.884M $2.71M

Revenue by Products

Product Q3-2021Q1-2022Q2-2025Q3-2025
Product and Services
Product and Services
 $0 ▲$0 ▲$0 ▲$0 ▲
Telehealth Revenue Net
Telehealth Revenue Net
 $20.00M ▲$20.00M ▲$0 ▼$0 ▲
Work Simpli Revenue Net
Work Simpli Revenue Net
 $10.00M ▲$10.00M ▲$0 ▼$0 ▲
Cost of Telehealth Revenue
Cost of Telehealth Revenue
 $0 ▲$0 ▲$0 ▲$0 ▲
Cost of Work Simpli Revenue
Cost of Work Simpli Revenue
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has been climbing steadily over the past several years, and gross profit has grown even faster, which suggests the core business model is gaining traction and pricing is holding up. At the same time, operating losses have narrowed each year, moving the company much closer to break-even than it was a few years ago. Net losses are still present, but the trend is clearly toward smaller and more manageable deficits. Earnings per share remain negative but have improved meaningfully, reflecting both better cost control and scale starting to show up in the income statement.

Balance Sheet

Balance Sheet The balance sheet is still quite lean and reflects a small, growth-stage company. Cash makes up a large share of total assets, which is helpful, but overall asset levels are modest. The company has taken on some debt, introducing financial obligations that must be watched, especially given ongoing losses. Shareholder equity has recently dipped slightly negative, which is a sign of accumulated past losses and limited balance sheet cushion. In simple terms, the financial foundation is improving in operations but remains thin from a capital-structure standpoint.

Cash Flow

Cash Flow Cash generation has improved notably. Operating cash flow has shifted from meaningfully negative to positive in recent years, showing that the underlying business is starting to fund more of its own growth. Free cash flow has moved from clearly negative to roughly around break-even, even after accounting for modest investment in the business. Capital spending remains relatively light, which helps cash preservation but also means growth is being driven more by efficiency and scaling the existing platform than by heavy physical investment.

Competitive Edge

Competitive Edge LifeMD operates in a crowded telehealth space but has carved out a differentiated position. Its vertical integration—owning much of the care pathway from online visit to pharmacy fulfillment—gives it more control over quality, patient experience, and costs than many peers that outsource key pieces. The focus on high-demand areas like weight management, men’s health, and new entries into women’s and behavioral health allows it to concentrate resources and build expertise rather than trying to be a generalist telehealth provider. Real-time visits and ongoing relationships with patients further set it apart from “quick-visit” or purely text-based models, potentially supporting better adherence and retention. Partnerships with well-known pharma and wellness players add credibility and broaden its reach, but competition in telehealth and in GLP-1 weight-loss drugs remains intense.

Innovation and R&D

Innovation and R&D Innovation is at the center of LifeMD’s strategy. The company has built its own digital care platform, including an in-house medical group, pharmacy capabilities, and a proprietary health record system, all supported by workflow and AI tools to streamline care. It is actively expanding into new, high-growth verticals—weight management with GLP-1 drugs, women’s health, and behavioral health—often with tailored, programmatic offerings rather than one-off visits. The plan to unify its services into a single platform and marketplace, coupled with ongoing work on oral GLP-1 offerings and personalized therapies, illustrates a pipeline of product and technology initiatives. The key question is not whether innovation is happening—it clearly is—but whether the company can scale these initiatives efficiently and maintain quality and regulatory compliance as it grows.

Summary

LifeMD is transitioning from an early-stage, loss-making telehealth player toward a more mature, scale-driven platform with improving economics. Revenue and margins have moved in the right direction, and cash flow has strengthened to the point where operations are contributing meaningfully to funding the business. At the same time, the balance sheet remains thin, with limited equity and some emerging debt, leaving less room for large missteps. Strategically, the company appears well-positioned through vertical integration, specialty focus, and technology-driven care, with significant opportunities in weight management, women’s health, and behavioral health. The main uncertainties center on execution: the ability to sustain growth in a competitive, regulated space while turning consistent profitability and reinforcing the balance sheet over time.

NEWS

November 24, 2025 · 8:00 AM UTC

LifeMD Recognized by the 2025 Deloitte Technology Fast 500™ and by TIME's America's Growth Leaders of 2026

Read more

November 17, 2025 · 4:05 PM UTC

LifeMD Reports Third Quarter 2025 Results

Read more

November 17, 2025 · 8:00 AM UTC

LifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo Nordisk

Read more

November 10, 2025 · 8:00 AM UTC

LifeMD to Participate in the BTIG Digital Health Forum

Read more

November 5, 2025 · 5:15 PM UTC

LifeMD Reschedules Third Quarter 2025 Earnings Release and Conference Call to November 17

Read more